Hot Stocks To Watch Right Now

The shift in online shopping from desktop computers to mobile devices is surging again this year as 58.6% of Thanksgiving Day shoppers used their smartphones and tablets to make purchases. A record $449 million was rung up by 5:00 p.m. ET Thursday, with $322 million in sales recorded from smartphones and $127 million from tablets.

Total online sales reached $1.15 billion, up 13.6% year over year. Sales to desktop users totaled $702 million.

The data were posted by Adobe Digital Insights and the researchers till expect total Thanksgiving Day sales to reach or come close to $2 billion.

The less good news for retailers is that discounting is much higher this year. Tablets, TVs, toys, and pet care items are much more heavily discounted than last year with most of the promotional pricing being revealed by search advertising and shopper help sites.

Hot Stocks To Watch Right Now: Summer Infant Inc.(SUMR)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Childrens Placeoutperforming last year before leveling off into a range while mid cap peerCarter’s, Inc (NYSE: CRI) is nearing previous highs againand small cap Summer Infant, Inc (NASDAQ: SUMR) is well below previous highs:

Hot Stocks To Watch Right Now: Pacific Gas & Electric Co.(PCG)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was PG&E Corp. (NYSE: PCG) which rose about 6% to $45.08. The stocks 52-week range is $37.30 to $71.57. Volume was nearly 13 million compared to the daily average volume of 6.8 million.

  • [By David Dittman]

    PG&E Corp (NYSE: PCG), Edison International (NYSE: EIX) and Sempra Energy (NYSE: SRE) are the parent entities of California’s investor-owned utilities.

  • [By Jon C. Ogg]

    PG&E Corp. (NYSE: PCG), the parent of Pacific Gas & Electric, has been the focus of many regulatory actions in California over time. And power lines have been targeted, and PG&E shares dropped after the 2017 wildfires in the state.

Hot Stocks To Watch Right Now: National Grid Transco, PLC(NGG)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Among utilities, National Grid (NGG) is my best pick for 2017, as it’s an almost perfect hedge against uncertainty. It’s insulated from changes in government interest rates. It can be both an inflation hedge and a play on a strong dollar.

  • [By Lisa Levin]

    Tuesday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from National Grid plc (ADR) (NYSE: NGG) and Dominion Resources, Inc. (NYSE: D).

  • [By Travis Hoium]

    National Grid (NYSE:NGG) came out with some interesting information last week, saying 2.4 GW of distributed solar was added in the U.K. between February 2016 and February 2017 and another 1.5 GW is expected in the next year. The U.K. isn’t exactly a hotbed for solar activity, but it’s growing as an important market.

Hot Stocks To Watch Right Now: Diageo plc(DEO)

Advisors’ Opinion:

  • [By Mark Fritz]

    Distillers

    Brown-Forman Corporation (NYSE: BF.B): Hold.
    Price Target: $46.00.

    Davide Campari Milano SpA (ADR) (OTC: DVDCY): Buy.
    Price Target: 7.40 euros.

    Diageo plc (ADR) (NYSE: DEO): Hold.
    Price Target: 25.50 pounds.

    PERNOD RICARD EUR1.55 (OTC: PDRDF): Hold.
    Price Target: 98 euros.

    REMY COINTREAU EUR1.60 (OTC: REMYF): Hold.
    Price Target: 99 euros.

    The authors relied on U.S. Census data, industry sources and the National Survey on Drug Use and Health.

  • [By Jayson Derrick]

    Given this less than favorable outlook, the analysts downgrade Diageo plc (ADR) (NYSE: DEO)’s stock rating from Buy to Hold with a price target on the U.K.-listed stock of GBP25.50.

  • [By Leo Sun]

    Retirees should generally invest in companies with wide moats and solid dividends. In a previous article, I noted that AT&T and Unilever were easy-to-understand companies that were ideal for most retirement portfolios. Today, I’ll add two more companies to that list — alcoholic beverage giants Diageo (NYSE:DEO) and Anheuser-Busch InBev (NYSE:BUD).

Hot Stocks To Watch Right Now: Carter's, Inc.(CRI)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After running through their scenarios,Boruchow comes up with five losers from Trump’s tax plans: Carters (CRI), Urban Outfitters (URBN), Under Armour (UA), Fossil Group (FOSL) and Gap (GPS). He explains why:

Qumu Corp (QUMU) Files 10-K for the Fiscal Year Ended on December 31, 2017

Qumu Corp (NASDAQ:QUMU) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Qumu Corp provides enterprise video content management software to create, manage, secure, distribute and measure the success of videos. It also offers solutions that label, archive, distribute and protect content on CDs, DVDs and Blu-ray Discs. Qumu Corp has a market cap of $15.400 million; its shares were traded at around $1.64 with and P/S ratio of 0.57. Qumu Corp had annual average EBITDA growth of 30.50% over the past five years.

For the last quarter Qumu Corp reported a revenue of $7.23 million, compared with the revenue of $9.32 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $28.2 million, a decrease of 11.1% from the previous year. For the last five years Qumu Corp had an average revenue growth rate of 23.1% a year.

The reported loss per diluted share was $1.25 for the year, compared with the loss per share of $0.96 in the previous year. The Qumu Corp had an operating margin of -31.49%, compared with the operating margin of -35.86% a year before. The 10-year historical median operating margin of Qumu Corp is -33.68%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Qumu Corp has the cash and cash equivalents of $7.69 million, compared with $10.4 million in the previous year. The long term debt was $7.61 million, compared with $6.79 million in the previous year. Qumu Corp has a financial strength rank of 4 (out of 10).

At the current stock price of $1.64, Qumu Corp is traded at 66.7% discount to its historical median P/S valuation band of $4.93. The P/S ratio of the stock is 0.57, while the historical median P/S ratio is 1.64. The stock lost 33.33% during the past 12 months.

For the complete 20-year historical financial data of QUMU, click here.

Top Gold Stocks To Invest In Right Now

After rallying to a high of $1,365 an ounce this summer, gold has retraced most of its ascent and now stands just 7% above where it started the year. With it have gone some of the biggest names in the industry, though their stock values stand appreciably higher than where they were a year ago. Barrick Gold has nearly doubled in value, Newmont Mining is up 75% for the year, and streamer Franco Nevada gained nearly 25%:

ABX data by YCharts.

Running with a winner is often a good strategy, but there are three more gold stocks investors should consider for their portfolios not only because they can be bought cheap, but also for the potential they still hold for outsized returns.

Situated for the coming recovery

Unlike its peers, gold-mining giant Goldcorp (NYSE:GG) has had a lackluster year at best, sitting just 10% or so above the year’s starting point. Yet the miner has several things going for it that differentiate it from the others, such as having most of its top-producing mines in countries that are relatively politically stable.

Top Gold Stocks To Invest In Right Now: Pilot Gold Inc (PLGTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Wesdome Gold (OTC:WDOFF) is confirming the potential of its Kiena Deeps discovery with the latest batch of drill results from this venue. Itinerant Musings subscribers who joined us in this trade will be pleased. Treasury Metals (OTC:TSRMF) needs to find more underground ore to justify a construction decision of its Goliath gold project, and it’s doing just that as reported in the latest news release and explained in this article. NuLegacy Gold (OTCQX:NULGF) finally announced results from the twin hole of the Avocado discovery. A detailed discussion will be forthcoming for Itinerant Musings subscribers shortly. Pilot Gold (OTCPK:PLGTF) is making progress at its Goldstrike project in Utah. The latest set of results confirmed the Peg Leg and Covington targets as valid targets for further drilling. Arizona Mining (OTC:WLDVF) is countering controversy by releasing more drill results, and reporting the discovery of Taylor Deeps. The roller coaster continues.

Top Gold Stocks To Invest In Right Now: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

Top Gold Stocks To Invest In Right Now: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top Gold Stocks To Invest In Right Now: CME Group Inc.(CME)

Advisors’ Opinion:

  • [By David Zeiler]

    Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.

  • [By ]

    Sure, I will invest more in certain high-confidence picks than others, but without going overboard. This might limit the impact from a triple-digit winner in my High-Yield Investing portfolio, such as CME Group (Nasdaq: CME), where we are showing a 156% gain at last count, but it will also soften the blow from a laggard.

  • [By ]

    CME Group (Nasdaq: CME) is the world’s largest and most diverse futures exchange group, operating in four segments — the Chicago Mercantile Exchange, the Chicago Board of Trade, the New York Mercantile Exchange and the Commodity Exchange.

  • [By ]

    Market Exchanges like the CME Group (Nasdaq: CME) have just started allowing trading in bitcoin futures and could attract an entirely new type of retail user as well as allowing institutional clients access to the bitcoin theme. Exchanges make their money on transactional volume, so a bursting of the bitcoin bubble wouldn’t necessarily mean weakness for shares.

Top 5 Value Stocks To Buy Right Now

Baytex Energy (BTE) is a company that is highly leveraged to oil prices. With its large differentials for its Canadian oil production, its margins can change significantly with a more modest change in oil prices. For the time being though, the weaker Canadian dollar has offset much of effect of oil prices falling compared to a month ago.

Baytex is priced appropriately for the current oil strip, so upside versus its current share price depends on whether long-term oil prices go up from around $52. Although I believe that growing US production will make it difficult for oil prices to increase a huge amount from current levels, taking the over on $52 oil seems a reasonable proposition.

2017 At $50 Oil

If NYMEX oil averages $50 during 2017, it appears that Baytex would end up with approximately $733 million in revenue, including $8 million in positive hedge value. This compares with my previous estimate of $782 million in revenue at $55 oil.

Units

Top 5 Value Stocks To Buy Right Now: SodaStream International Ltd.(SODA)

Advisors’ Opinion:

  • [By Peter Graham]

    Israel based small cap home beverage carbonation stockSodastream International Ltd (NASDAQ: SODA) reported Q1 2017 earnings before the market opened this morning. Revenue increased 14.3% to $115.3 million driven by growth in each of the Company’s four geographic regions, partially offset by a negative foreign currency exchange impact mainly due to the weakening of the Euro/U.S. Dollar exchange rate compared to the same period in 2016. Net income increased 141.8% to $14.7 million.

  • [By Jeremy Bowman]

    SodaStream International(NASDAQ:SODA) blew the market away in 2016 as shares of the DIY soda-maker popped 142%, beating all but two stocks in the S&P 500.

  • [By Peter Graham]

    The Q4 2016 earnings report for Israel based small cap home beverage carbonation stockSodastream International Ltd (NASDAQ: SODA) is scheduled for before the market opens onWednesday (February 15). However, theIsrael connection along with changing consumer tastes havesent sharesfrom fizzy to being flat. On the other hand,Sodastream International climbed 16.22% after releasing third quarter earnings that easily topped Wall Street expectations after making efforts to revamp its image.

Top 5 Value Stocks To Buy Right Now: Evoke Pharma, Inc.(EVOK)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Cameron Saucier]

    Evoke (Nasdaq: EVOK) is a pharmaceutical company that develops drug candidates intended to treat gastrointestinal diseases. EVOK rose 73% last month after it announced positive guidance from the FDA for Gimoti, a patented nasal delivery drug that is intended to treat gastroparesis in adult women. The positive results were from a second pre-NDA (New Drug Application) meeting Evoke had with the FDA. EVOK is currently trading at $2.67 per share and is down 9.83% as of Jan. 9 YOY.

Top 5 Value Stocks To Buy Right Now: Douglas Dynamics Inc.(PLOW)

Advisors’ Opinion:

  • [By Lisa Levin] Related PLOW 18 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Gainers For Tuesday Douglas Dynamics Inc (PLOW) Chairman, President and CEO James L Janik Bought $59,5 of … (GuruFocus)
    Related TIF Your Luxury Brands Earnings Cheat Sheet Guggenheim Initiates Coverage On 21 Retail Stocks Tiffany & Co: China Market Will Drive Earnings Growth For The Next Decade (Seeking Alpha)

    It’s critical to know whether a stock you plan on buying has an ex-dividend status, because in case it does, the dividend would be paid out to the seller. The person who owns the stock on the ex-dividend date will be awarded the payment, which means that you’ll have to wait for the next dividend cycle to receive your first dividend payout from the company.

Top 5 Value Stocks To Buy Right Now: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By ]

    Arena Pharmaceuticals (Nasdaq: ARNA) has completed Phase 2 evaluation of its Ralinepag program for pulmonary arterial hypertension (PAH). The drug was granted orphan status by the U.S. Food and Drug Administration in 2014 which brings faster case review and increased patent protection.

  • [By Lisa Levin]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap obesity drug stock Arena Pharmaceuticals, Inc (NASDAQ: ARNA) is scheduled for after the market closes onTuesday (March 14th). Last June,Arena Pharmaceuticals announced a strategic shifting of priorities to emphasize its proprietary clinical stage pipeline and the implementation of additional cost reductions to streamline the organization to support its development programs. Among the actions to be taken is the layoff of 73% of the companys workforce which will cost approximately $6.1 million.

  • [By Keith Speights]

    Eisai partnered with Arena Pharmaceuticals (NASDAQ:ARNA) several years ago on obesity drug Belviq. The drug won U.S. regulatory approval in 2012, but sales have been underwhelming. As a result, Arena sold Belviq to Eisai earlier this year.

Top 5 Value Stocks To Buy Right Now: Beasley Broadcast Group Inc.(BBGI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Beasley Broadcast Group Inc (NASDAQ: BBGI) and Lee Enterprises, Incorporated (NYSE: LEE).

  • [By Benzinga News Desk]

    Beasley Broadcast Group (NASDAQ: BBGI) and Greater Media have entered into a definitive agreement under which Beasley will acquire all of the outstanding stock of Greater Media for approximately $240 million.

Best Oil Stocks To Own For 2018

It’s expected to be the biggest IPO in history. And officials in Saudi Arabia were hoping it would happen this year.

Proceeds from Aramco’s stock market listing have been earmarked to fund the diversification of the Saudi economy — the centerpiece of Crown Prince Mohammed bin Salman’s Vision 2030 program of reform.

But the sale of shares in the world’s biggest oil company could slip into 2019. The Financial Times and New York Times both reported Monday that the timetable could be delayed.

In a statement on Monday, Saudi Aramco said it continues to review options for the listing, adding that “appropriate decisions will be made in due course.” But it did not comment on the timing.

Here are three reasons why investors may have to wait a little longer to get their hands on its shares.

1. Size and complexity of the deal

Saudi officials have been targeting a value of $2 trillion for Aramco. Selling just 5% would raise $100 billion, dwarfing all previous IPOs, including Alibaba’s (BABA) $25 billion sale in 2014.

Best Oil Stocks To Own For 2018: Apache Corporation(APA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer and the AAP team say Apache’s (APA) mixed results are a buying opportunity. Find out what they’re telling their investment club members with a free trial subscription to Action Alerts PLUS.

  • [By WWW.THESTREET.COM]

    Cramer and the AAP team are detailing their outlook for portfolio energy names Apache (APA) and Cimarex (XEC) . Find out what they’re telling their investment club members with a free trial subscription to Action Alerts PLUS.

  • [By WWW.THESTREET.COM]

    Cramer and Jack Mohr think Apache’s (APA) management has positioned the company for growth through both innovation and efficiency. Read what they are telling their investment club members with a free subscription to Action Alerts PLUS.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Friday Apache Corp. (NYSE: APA) which rose about 5.7% to $44.22. The stocks 52-week range is $38.14 to $69.00. Volume was5 million compared to its average volume of 3.3 million.

  • [By WWW.THESTREET.COM]

    Cramer and the AAP team say news and caution are weighing on energy and health-care sectors. Find out what they’re telling their investment club members about Apache (APA) , Cimarex (XEC) , Arconic (ARNC) and Allergan (AGN) with a free trial subscription to Action Alerts PLUS.

  • [By WWW.THESTREET.COM]

    Cramer and the Action Alerts PLUS team say they still believe in their embattled Permian names, Cimarex (XEC) and Apache (APA) , both of which have benefited from a slow rotation in recent weeks. These names can produce and profit here. Schlumberger (SLB) remains best in class and Magellan Midstream Partners just might be the best way to play oil given that the pipelines will be needed to transport the new wave of oil able to be drawn out of the ground from increasingly efficient American producers. Get in on the discussion by getting a free trial subscription to Action Alerts PLUS.

Best Oil Stocks To Own For 2018: Williams Partners L.P.(WPZ)

Advisors’ Opinion:

  • [By Ben Levisohn]

    In a release after the close on Monday, Williams and Williams Partners (WPZ) made several announcements, including: 1) outlining managements plan to financially reposition and simplify the franchises GP/LP structure in an ~$11.4 billion transaction (not subject to any additional approvals), 2) adjustments to Williams and Williams Partners’ dividend and distribution payouts, 3) initiating a ~$2+ billion William equity raise to fund a further Williams investment in Williams Partners, 4) noted other potential upcoming changes, including the sale of ~$2 billion in non-core assets in 2017, and 5) provided several forms of updated 2017 guidance…

Best Oil Stocks To Own For 2018: Talisman Energy Inc.(TLM)

Advisors’ Opinion:

  • [By Jayson Derrick]

    On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.

Best Oil Stocks To Own For 2018: Halliburton Company(HAL)

Advisors’ Opinion:

  • [By ]

    KBR (NYSE: KBR)
    Though an under-the-radar name, KBR was the construction arm of oilfield services giant Halliburton (NYSE: HAL) before being spun off. With a consolidated market cap of $2.6 billion, KBR describes itself, per its website, as a “global provider of differentiated professional services and technologies within the Government Services and Hydrocarbon sectors.”

  • [By Lee Jackson]

    These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).

  • [By Matthew DiLallo]

    Following a series of M&A announcements in the oilfield-services sector since the onset of the oil market downturn, French oil-field service company Technip and U.S. oilfield equipment company FMC Technologies (NYSE:FTI) hooked up in an all-stock deal valuing the combined company at $13 billion. Shareholders of each company will own 50% of the combined entity, to be named TechnipFMC, which implies a roughly $6.5 billion acquisition valuation for each entity. The transaction, which should close early next year, will “combine Technip’s innovative systems and solutions, state-of-the-art assets, engineering strengths, and project management capabilities with FMC Technologies’ leading technology, manufacturing, and service capabilities.” Further, it should save $400 million in annual costs by 2019. Moreover, it will enable the combined company to compete better against larger oil-field service rivals Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), and Schlumberger (NYSE:SLB), which have all gained strength during the downturn either through M&A activities or cost savings initiatives.

  • [By Lisa Levin]

    Halliburton Company (NYSE: HAL) reported better-than-expected earnings for its first quarter on Monday.

    Halliburton posted adjusted earnings of $0.04 per share in the quarter on revenue of $4.28 billion; Analysts were expecting the company to earn $0.03 per share on revenue of $4.26 billion.

  • [By Tyler Crowe]

    2016 was an interesting year for Halliburton (NYSE:HAL). Not only did the oil-field services company work through one of the largest downturns in the history of oil and gas, but it also had to deal with the financial fallout from a major acquisition blowing up in its face. When it reported fourth-quarter and fiscal 2016 earnings this week, the company showed that it had taken a big blow, but was ready to move on to the next big thing in the oil and gas market. Let’s take a quick look at the company’s results for the year that was, and see what could be in store in the coming quarters.

  • [By Lisa Levin]

    Halliburton Company (NYSE: HAL) reported stronger-than-expected profit for its third quarter on Monday.

    Halliburton posted quarterly adjusted earnings of $0.42 per share on revenue of $5.44 billion. However, analysts expected earnings of $0.37 per share on revenue of $5.35 billion.

Tokyo consumer price gains lost steam in March

TOKYO–Tokyo’s core consumer prices rose in March at a slightly slower pace, indicating a lack of extra momentum in nationwide inflation after it reached halfway to the Bank of Japan’s 2% target last month.

The core CPI, which excludes fresh food prices, rose 0.8% in March from a year earlier, data from the Ministry of Internal Affairs and Communications showed Friday.

The result came in lower than a 0.9% forecast by economists polled by the Nikkei and February’s 0.9% rise. The core CPI excludes volatile fresh food prices.

Tokyo CPI is seen as an early indicator of nationwide numbers. In recent months, the national index has been around 0.2 percentage points higher than the Tokyo result.

The nationwide core CPI for February rose 1% on year, the fastest pace since August 2014, after excluding the impact of the 2014 sales tax increase, according to ministry data released last week.

Separate employment data showed slightly less tightness in the labor market, though unemployment remains near a multi-decade low.

Japan’s jobless rate was 2.5% in February, after falling to 2.4% in January, the lowest level since April 1993.

Another indicator showed there were 158 jobs available to 100 job seekers in February, slightly lower than the 44-year high of 159 in the previous month.

Policy makers hope tightness in the labor market will help put upward pressure on wages and give a tailwind to Japan’s efforts to spur a virtuous economic cycle in which rising wages, consumption and prices create a feedback loop.

Write to Megumi Fujikawa at megumi.fujikawa@wsj.com

The poisonous myth of confidence culture

Women are constantly being told they need to be more confident.

Social media and pop culture send the same message over and over: feel more confident and you’ll be more successful. Keep “confidence logs” and “brag books.” Dress for success. Power pose.

But in the last six months, the #MeToo movement has ignited a nationwide discussion about the structural barriers inhibiting women’s success pervasive cultures of harassment, limited access to male leaders, careers stalled by postponed promotions and overlooked raises. All problems a power pose can’t fix.

Instagram mantras, confidence-tracking apps and self-monitoring tips from books like “Lean In” and “The Confidence Code” have created an environment that puts too much pressure on the individual, according to London School of Economics Professor Shani Orgad. She calls it “confidence culture.”

“These women have internalized the blame rather than the revolution,” Orgad says of “confidence culture” followers.

A ‘confidence coach’ taught me to be more self-confident

Self-confidence or self-deception?

The promise of these self-confidence strategies is simple: believe in yourself, or fake it until you do, and boom success unlocked.

But self-confidence, and its companion feeling, self-efficacy, or the ability to actually achieve goals, doesn’t come out of the box like that, says David Ballard, assistant executive director for organizational excellence at the American Psychological Association. Especially for women and people of color, there are systemic barriers stalling their success, regardless of their own confidence in their abilities.

How a woman’s appearance can affect her career

“We know opportunities are not equal, so we can prepare individuals to address this and be successful,” he says. “But if we don’t simultaneously address the systemic issues, it’s an uphill battle for them.”

Other things outside an employee’s control like seeing role models similar to them succeed, or getting opportunities to test new skills and grapple with new challenges through “mastery experiences,” as Ballard calls them help develop self-confidence.

In a recent survey from the APA, 89% of men and 85% of women said they had the technical skills necessary to do their jobs well. But when asked if their employers had given them opportunities to learn new abilities they’d need for future career development, far fewer women than men reported seeing those opportunities.

And even when women “perform” assertiveness and other qualities we associate with self-confidence, it doesn’t always work in their favor. Research shows there’s often a backlash against women who act this way.

So in other words, those confidence exercises could make you feel great about your qualifications, but they won’t get you the promotion.

Countering the culture

That’s not to say women should balk at the occasional self-esteem boost, Ballard says. And every personality is different: some people may feel more energized by writing or repeating affirmations, while others may learn new skills when they read a confidence self-help book or ask for feedback and guidance on their executive presence.

As Ballard puts it, “The individual things are still important.”

“The individual needs to develop the skills they need, they need to have the experiences that are going to lead to success, but you can’t put the onus only on the individual,” he says. “We have to make changes to the system as well.”

But in decoding these “confidence culture” messages, confidence strategies can only do so much. Often, they’re hiding the bigger picture.

Hot Biotech Stocks To Watch For 2018

My clear choice for a Top Pick for income investing is a closed-end fund that invests in a variety of both public and private companies doing work in the life sciences sector, asserts Nate Pile, editor of Nate’s Notes.

Tekla Life Sciences Investors (HQL) represents an outstanding way for investors who want to be involved in biotech, but don’t like the high levels of stress that come into play when owning individual stocks in the sector.

The fund allows investors to participate in the growth of this important industry without having to endure as much volatility.  

Along with this exposure to the biotech space, the fund makes quarterly distributions at a rate of 2% of the fund’s net assets to shareholders each quarter. Though shareholders can specifically request to be paid in cash instead, the default is to have the payout reinvested in new shares.

Hot Biotech Stocks To Watch For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

Hot Biotech Stocks To Watch For 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Hot Biotech Stocks To Watch For 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.

  • [By Ben Levisohn]

    Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By WWW.THESTREET.COM]

    Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.

    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

Hot Biotech Stocks To Watch For 2018: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Monica Gerson]

    Medivation Inc (NASDAQ: MDVN) is said to have spurned recent takeover approach from France’s Sanofi SA (ADR) (NYSE: SNY), according to sources as reported by Bloomberg on Tuesday. Sanofi wants Medivation’s treatments for hard-to-cure cancers, the sources said. Medivation shares surged 8.46 percent to $49.60 in the after-hours trading session, while Sanofi shares fell 0.59 percent to $42.02 in after-hours trading.

  • [By Ben Levisohn]

    Reports suggest that Gilead Sciences (GILD) and Celgene (CELG) have joined the bidding process forMedivation (MDVN), one that already includes (maybe) Amgen (AMGN), and of course Sanofi (SNY), which is trying to throw out Medivation’s board. Of the three biotech giants, Citigroup’s Robyn Karnauskas and team argue that Amgen is best positioned to win the battle. They explain why:

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    PACCAR Inc (NASDAQ: PCAR) Aug16 52.5 Puts: 10000 @ ASK $1.70: 10k traded vs 335 OI: Earnings 7/26 $54.94 Ref
    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Jul16 345 Puts: 949 @ ASK $8.70: 1003 traded vs 55 OI: Earnings 8/2 $360.20 Ref
    NVIDIA Corporation (NASDAQ: NVDA) Fri 6/24 47.0 Puts (Wkly) Sweep: 689 @ ASK $1.12: 3758 traded vs 136 OI: Earnings 8/4 $46.69 Ref
    Medivation Inc (NASDAQ: MDVN) Sep16 55.0 Puts: 4000 @ Above Ask! $3.40: 5303 traded vs 716 OI: Earnings 8/4 $59.44 Ref
    Expeditors International of Washington (NASDAQ: EXPD) Aug16 47.0 Puts Sweep: 950 @ ASK $1.35: 973 traded vs 381 OI: Earnings 8/2 $48.15 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Ben Levisohn]

    Medivation (MDVN) has soared 20% to $80.41 after agreeing to be purchased for $14 billion, or $81.50 a share, by Pfizer (PFE). Pfizer has declined 0.7% to $34.75.

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

CBTX Inc (CBTX) Files 10-K for the Fiscal Year Ended on December 31, 2017

CBTX Inc (NASDAQ:CBTX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. CBTX Inc is a bank holding company that operates through its wholly-owned subsidiary, CommunityBank of Texas. It focuses on providing commercial banking solutions to small and mid-sized businesses and professionals. CBTX Inc has a market cap of $714.930 million; its shares were traded at around $28.79 with a P/E ratio of 18.10 and P/S ratio of 7.71. The dividend yield of CBTX Inc stocks is 0.17%.

For the last quarter CBTX Inc reported a revenue of $31.3 million, compared with the revenue of $29.07 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $122.0 million, an increase of 4% from last year.

The reported diluted earnings per share was $1.22 for the year. The CBTX Inc enjoyed an operating margin of 36.09%, compared with the operating margin of 33.44% a year before. The 10-year historical median operating margin of CBTX Inc is 32.20%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, CBTX Inc has the cash and cash equivalents of $326.2 million, compared with $382.7 million in the previous year. The long term debt was $6.73 million, compared with $34.4 million in the previous year. The interest coverage to the debt is 5. CBTX Inc has a financial strength rank of 6 (out of 10).

For the complete 20-year historical financial data of CBTX, click here.